The loss of Karyopharm Therapeutics under GAAP for the 3 months of 2022 was $41.399 million, down 27.9% from $57.414 million in the previous year. Revenue increased 2.1 times to $47.67 million from $23.26 million a year earlier.

Karyopharm Therapeutics's GAAP loss for 2021 was $124.088 million, down 36.8% from $196.273 million in the previous year. Revenue increased 94.1% to $209.819 million from $108.085 million a year earlier.

The FDA has granted orphan drug status to eltanexor, which is being developed by Karyopharm Therapeutics. The drug is intended to treat myelodysplastic syndromes with a risk of progression to acute myeloid leukemia. Drugs with this status can receive grants from the FDA to cover clinical trial costs, tax credits and seven years of market exclusivity in the U...

Karyopharm Therapeutics has granted the Menarini Group exclusive rights to commercialize NEXPOVIO in Europe, Latin America and other key countries. NEXPOVIO is indicated for the treatment of multiple myeloma in adults. Karyopharm will receive $75 million, as well as up to another $202.5 million when the drug's future development milestones are achieved and t...